niacinamide has been researched along with Idiopathic Parkinson Disease in 27 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The primary outcome was safety, defined as the frequency of moderate and severe adverse events." | 3.30 | NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease. ( Af Geijerstam, SA; Berven, H; Dölle, C; Haugarvoll, K; Kverneng, S; Sheard, E; Skeie, GO; Søgnen, M; Tzoulis, C, 2023) |
| " To estimate the N-methylation ability for azaheterocyclic amines in parkinsonian patient, nicotinamide was dosed with 100 mg to 26 parkinsonians and 20 controls consisted of 16 other neurogenic disease patients and 4 healthy volunteers." | 2.69 | N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test. ( Aoyama, K; Fukushima, S; Hayase, N; Kobayashi, S; Matsubara, K; Ohta, S; Okada, K; Satomi, M; Shimizu, K; Shiono, H; Uezono, T; Yamaguchi, S, 2000) |
| "This increase may be part genetic predisposition, and part induction, by excessive exposure to its substrates (particularly nicotinamide) or stress." | 2.43 | Parkinson's disease: the first common neurological disease due to auto-intoxication? ( Cartwright, LS; Ramsden, DB; Williams, AC, 2005) |
| "Creatine has been shown to be effective in several animal models of neurodegenerative diseases and currently is being evaluated in early stage trials in PD." | 2.42 | Bioenergetic approaches for neuroprotection in Parkinson's disease. ( Beal, MF, 2003) |
| "Parkinson's disease was induced by injection of MPTP in adult male C57BL/6 mice, nicotinamide (500 mg/kg,i." | 1.38 | [Protective effect of nicotinamide in a mouse Parkinson's disease model]. ( Jin, JH; Liang, J; Lu, Y; Luo, JH; Xu, J; Xu, SQ, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (14.81) | 18.7374 |
| 1990's | 4 (14.81) | 18.2507 |
| 2000's | 7 (25.93) | 29.6817 |
| 2010's | 6 (22.22) | 24.3611 |
| 2020's | 6 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Brakedal, B | 1 |
| Dölle, C | 2 |
| Riemer, F | 1 |
| Ma, Y | 1 |
| Nido, GS | 1 |
| Skeie, GO | 2 |
| Craven, AR | 1 |
| Schwarzlmüller, T | 1 |
| Brekke, N | 1 |
| Diab, J | 1 |
| Sverkeli, L | 1 |
| Skjeie, V | 1 |
| Varhaug, K | 1 |
| Tysnes, OB | 1 |
| Peng, S | 1 |
| Haugarvoll, K | 2 |
| Ziegler, M | 1 |
| Grüner, R | 1 |
| Eidelberg, D | 1 |
| Tzoulis, C | 2 |
| Talavera Andújar, B | 1 |
| Aurich, D | 1 |
| Aho, VTE | 1 |
| Singh, RR | 1 |
| Cheng, T | 1 |
| Zaslavsky, L | 1 |
| Bolton, EE | 1 |
| Mollenhauer, B | 1 |
| Wilmes, P | 1 |
| Schymanski, EL | 1 |
| Fathi, M | 1 |
| Vakili, K | 1 |
| Yaghoobpoor, S | 1 |
| Tavasol, A | 1 |
| Jazi, K | 1 |
| Hajibeygi, R | 1 |
| Shool, S | 1 |
| Sodeifian, F | 1 |
| Klegeris, A | 1 |
| McElhinney, A | 1 |
| Tavirani, MR | 1 |
| Sayehmiri, F | 1 |
| Delignat-Lavaud, B | 1 |
| Kano, J | 1 |
| Ducrot, C | 1 |
| Massé, I | 1 |
| Mukherjee, S | 1 |
| Giguère, N | 1 |
| Moquin, L | 1 |
| Lévesque, C | 1 |
| Burke, S | 1 |
| Denis, R | 1 |
| Bourque, MJ | 1 |
| Tchung, A | 1 |
| Rosa-Neto, P | 1 |
| Lévesque, D | 1 |
| De Beaumont, L | 1 |
| Trudeau, LÉ | 1 |
| Berven, H | 1 |
| Kverneng, S | 1 |
| Sheard, E | 1 |
| Søgnen, M | 1 |
| Af Geijerstam, SA | 1 |
| Willyard, C | 1 |
| Schöndorf, DC | 1 |
| Ivanyuk, D | 1 |
| Baden, P | 1 |
| Sanchez-Martinez, A | 1 |
| De Cicco, S | 1 |
| Yu, C | 1 |
| Giunta, I | 1 |
| Schwarz, LK | 1 |
| Di Napoli, G | 1 |
| Panagiotakopoulou, V | 1 |
| Nestel, S | 1 |
| Keatinge, M | 1 |
| Pruszak, J | 1 |
| Bandmann, O | 1 |
| Heimrich, B | 1 |
| Gasser, T | 1 |
| Whitworth, AJ | 1 |
| Deleidi, M | 1 |
| Lehmann, S | 1 |
| Costa, AC | 1 |
| Celardo, I | 1 |
| Loh, SH | 1 |
| Martins, LM | 1 |
| Wallach, I | 1 |
| Jaitly, N | 1 |
| Lilien, R | 1 |
| Liu, Z | 1 |
| Hamamichi, S | 1 |
| Lee, BD | 1 |
| Yang, D | 1 |
| Ray, A | 1 |
| Caldwell, GA | 1 |
| Caldwell, KA | 1 |
| Dawson, TM | 1 |
| Smith, WW | 1 |
| Dawson, VL | 1 |
| Xu, J | 1 |
| Xu, SQ | 1 |
| Liang, J | 1 |
| Lu, Y | 1 |
| Luo, JH | 1 |
| Jin, JH | 1 |
| Sheline, CT | 1 |
| Zhu, J | 1 |
| Zhang, W | 1 |
| Shi, C | 1 |
| Cai, AL | 1 |
| Beal, MF | 1 |
| Williams, AC | 5 |
| Ramsden, DB | 3 |
| Cartwright, LS | 1 |
| Willets, JM | 1 |
| Lunec, J | 1 |
| Griffiths, HR | 1 |
| Pall, HS | 1 |
| Steventon, GB | 1 |
| Green, S | 2 |
| Buttrum, S | 2 |
| Molloy, H | 2 |
| Waring, RH | 1 |
| Fukushima, T | 3 |
| Tawara, T | 1 |
| Isobe, A | 1 |
| Hojo, N | 1 |
| Shiwaku, K | 1 |
| Yamane, Y | 1 |
| Aoyama, K | 1 |
| Matsubara, K | 1 |
| Okada, K | 1 |
| Fukushima, S | 1 |
| Shimizu, K | 1 |
| Yamaguchi, S | 1 |
| Uezono, T | 1 |
| Satomi, M | 1 |
| Hayase, N | 1 |
| Ohta, S | 1 |
| Shiono, H | 1 |
| Kobayashi, S | 1 |
| Kaetsu, A | 1 |
| Lim, H | 1 |
| Moriyama, M | 1 |
| Steventon, G | 1 |
| Sturman, S | 1 |
| Waring, R | 1 |
| Pall, H | 1 |
| Williams, A | 1 |
| Tzavellas, O | 1 |
| Torizuka, K | 1 |
| Hamamoto, K | 1 |
| Morita, R | 1 |
| Mukai, T | 1 |
| Kosaka, T | 1 |
| Handa, J | 1 |
| Nishitani, H | 1 |
| Cotzias, GC | 1 |
| Lawrence, WH | 1 |
| Papavasiliou, PS | 1 |
| Düby, SE | 1 |
| Braĭko, IV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| NOPARK Open Label Extension Study[NCT05546567] | 400 participants (Anticipated) | Interventional | 2022-09-28 | Recruiting | |||
| NAD-PARK: A Double-blinded Randomized Pilot Trial of NAD-supplementation in Drug naïve Parkinson's Disease[NCT03816020] | 30 participants (Actual) | Interventional | 2019-03-09 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for niacinamide and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Dynamic changes in metabolites of the kynurenine pathway in Alzheimer's disease, Parkinson's disease, and Huntington's disease: A systematic Review and meta-analysis.
Topics: 3-Hydroxyanthranilic Acid; Adenosine; Alzheimer Disease; Humans; Huntington Disease; Hydroxyindoleac | 2022 |
Bioenergetic approaches for neuroprotection in Parkinson's disease.
Topics: Acetylcarnitine; Coenzymes; Creatine; Energy Metabolism; Free Radicals; Ginkgo biloba; Humans; Mitoc | 2003 |
Autotoxicity, methylation and a road to the prevention of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Dopamine Agents; Humans; Methylation; Niacina | 2005 |
Parkinson's disease: the first common neurological disease due to auto-intoxication?
Topics: Brain; Environment; Genetic Predisposition to Disease; Humans; Inactivation, Metabolic; Methyltransf | 2005 |
[Elucidation of paraquat poisoning mechanism and development of the neuronal death model].
Topics: Animals; Chaperonin 60; Disease Models, Animal; Electron Transport Complex I; Herbicides; Humans; Li | 2002 |
3 trials available for niacinamide and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Topics: Dietary Supplements; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds | 2022 |
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Topics: Dietary Supplements; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds | 2022 |
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Topics: Dietary Supplements; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds | 2022 |
The NADPARK study: A randomized phase I trial of nicotinamide riboside supplementation in Parkinson's disease.
Topics: Dietary Supplements; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds | 2022 |
NR-SAFE: a randomized, double-blind safety trial of high dose nicotinamide riboside in Parkinson's disease.
Topics: Double-Blind Method; Humans; NAD; Niacinamide; Parkinson Disease; Pyridinium Compounds | 2023 |
N-methylation ability for azaheterocyclic amines is higher in Parkinson's disease: nicotinamide loading test.
Topics: Aged; Aging; Aldehyde Oxidase; Aldehyde Oxidoreductases; Brain; Carbolines; Chromatography, High Pre | 2000 |
19 other studies available for niacinamide and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Studying the Parkinson's disease metabolome and exposome in biological samples through different analytical and cheminformatics approaches: a pilot study.
Topics: Aged; Alanine; Betaine; Cheminformatics; Exposome; Humans; Metabolome; Metabolomics; Neurodegenerati | 2022 |
Synaptotagmin-1-dependent phasic axonal dopamine release is dispensable for basic motor behaviors in mice.
Topics: Animals; Caffeine; Calcium; Corpus Striatum; Dopamine; Mice; Neostriatum; Niacinamide; Parkinson Dis | 2023 |
How gut microbes could drive brain disorders.
Topics: alpha-Synuclein; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Autism Spectrum Disorder | 2021 |
The NAD+ Precursor Nicotinamide Riboside Rescues Mitochondrial Defects and Neuronal Loss in iPSC and Fly Models of Parkinson's Disease.
Topics: Animals; Autophagy; Disease Models, Animal; Dopaminergic Neurons; Drosophila melanogaster; Endoplasm | 2018 |
Parp mutations protect against mitochondrial dysfunction and neurodegeneration in a PARKIN model of Parkinson's disease.
Topics: Animals; Blotting, Western; Brain; Dietary Supplements; Disease Models, Animal; Dopaminergic Neurons | 2016 |
A structure-based approach for mapping adverse drug reactions to the perturbation of underlying biological pathways.
Topics: Breast Neoplasms; Computational Biology; Databases, Factual; Diabetes Mellitus, Type 2; Drug-Related | 2010 |
Inhibitors of LRRK2 kinase attenuate neurodegeneration and Parkinson-like phenotypes in Caenorhabditis elegans and Drosophila Parkinson's disease models.
Topics: Animals; Animals, Genetically Modified; Benzenesulfonates; Caenorhabditis elegans; Cell Survival; Di | 2011 |
[Protective effect of nicotinamide in a mouse Parkinson's disease model].
Topics: Animals; Corpus Striatum; Disease Models, Animal; Dopamine; Male; Mice; Mice, Inbred C57BL; Motor Ac | 2012 |
Mitochondrial inhibitor models of Huntington's disease and Parkinson's disease induce zinc accumulation and are attenuated by inhibition of zinc neurotoxicity in vitro or in vivo.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Carrier Proteins; Cation Transport Proteins; | 2013 |
Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases.
Topics: Animals; Choline; Embryonic Development; Epigenesis, Genetic; Evolution, Molecular; Homeostasis; Hum | 2005 |
Neurotoxicity of nicotinamide derivatives: their role in the aetiology of Parkinson's disease.
Topics: 1-Methyl-4-phenylpyridinium; Animals; Cell Survival; Humans; Isomerism; Kinetics; L-Lactate Dehydrog | 1993 |
N-methylation of pyridines and Parkinson's disease.
Topics: Humans; Methylation; Methyltransferases; Niacinamide; Parkinson Disease; Pyridines; Pyridones | 1993 |
Radical formation site of cerebral complex I and Parkinson's disease.
Topics: Animals; Brain; Cattle; Electrophoresis, Polyacrylamide Gel; Hydrogen-Ion Concentration; Hydroxyl Ra | 1995 |
Possible role of 1-methylnicotinamide in the pathogenesis of Parkinson's disease.
Topics: Animals; Brain; Cell Fractionation; Cytosol; Dopamine; Dose-Response Relationship, Drug; Gas Chromat | 2002 |
N-methylation of pyridines in Parkinson's disease.
Topics: Humans; Methylation; Middle Aged; Niacinamide; Parkinson Disease | 1991 |
[The effect of vitamin B 12 in combination with 4-chlortestosterone acetate on Parkinson's syndrome and hyperkinesia].
Topics: Adult; Aged; Blood Pressure; Body Weight; Drug Tolerance; Female; Folic Acid; Humans; Hyperkinesis; | 1967 |
Regional cerebral blood flow measurement with xenon 133 and the scinticamera.
Topics: Adult; Aged; Arteriosclerosis; Brain; Cerebrovascular Circulation; Computers; Female; Humans; Hydroc | 1971 |
Nicotinamide ineffective in parkinsonism.
Topics: Adult; Humans; Hypotension; Middle Aged; Niacinamide; Parkinson Disease | 1972 |
[Phenatine treatment of parkinsonism].
Topics: Adult; Humans; Male; Middle Aged; Niacinamide; Parkinson Disease | 1973 |